Immunology

About our Immunology efforts

Our R&D strategy is inspired by the courage of patients living with debilitating, life-limiting auto-immune conditions. We are taking bold steps to deliver scientific breakthroughs that target, repair and prevent these diseases. Specific areas of focus include inflammatory skin diseases and inflammatory bowel diseases such as Crohn’s Disease and Ulcerative Colitis.

Selection of projects in February 2024

Phase 1 studies are usually designed with an emphasis on the assessment of safety and tolerability of an investigational drug in a small group of people for the first time. It can include healthy participants or participants with the disease.

PD-1 antibody

TREM-1 Antibody

Immunomodulator

Phase 2 studies are usually designed to begin to evaluate the efficacy of an investigational drug in a higher number of participants with the disease, and often used to obtain dose-ranging information. Safety also continues to be assessed during this phase.

BI 706321